Equity Overview
Price & Market Data
Price: $1.26
Daily Change: -$0.08 / 6.35%
Daily Range: $1.25 - $1.39
Market Cap: $30,999,024
Daily Volume: 152,756
Performance Metrics
1 Week: -30.00%
1 Month: -39.71%
3 Months: 23.81%
6 Months: 7.69%
1 Year: 80.88%
YTD: 5.00%
Company Details
Employees: 15
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.